Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia

3 Oct 2017

Abstract excerpt

Abstract Purpose: BCR-ABL+ B-ALL leukemic cells are highly dependent on the expression of endogenous antiapoptotic MCL-1 to promote viability and are resistant to BH3-mimetic agents such as navitoclax (ABT-263) that target BCL-2, BCL-XL, and BCL-W. However, the survival of most normal blood cells and other cell types is also dependent on Mcl-1. Despite the requirement for MCL-1 in these cell types, initial...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Immune Cell Function and Interaction
Share to Signaling Pathways in Disease

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28974549
DOI: 10.1158/1078-0432.ccr-17-1231

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 9 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic LeukemiaPMID 28974549Read ↗

Heme-Sensing Pathway Modulates Susceptibility of Poor Prognosis B-Lineage Acute Leukemia to BH3-MimeticsSemantic proximity Read ↗

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignanciesSemantic proximity Read ↗

Co-targeting of Bcl-2 and mTOR pathway triggers synergistic apoptosis in BH3 mimetics resistant acute lymphoblastic leukemiaSemantic proximity Read ↗

Idasanutlin and navitoclax induce synergistic apoptotic cell death in T-cell acute lymphoblastic leukemiaSemantic proximity Read ↗

A screening-based approach to circumvent tumor microenvironment-driven intrinsic resistance to BCR-ABL+ inhibitors in Ph+ acute lymphoblastic leukemia.Semantic proximity Read ↗

Cell and Molecular Determinants of <i>In Vivo</i> Efficacy of the BH3 Mimetic ABT-263 against Pediatric Acute Lymphoblastic Leukemia XenograftsSemantic proximity Read ↗

In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cellsSemantic proximity Read ↗

Determinants of Sensitivity to DZNep Induced Apoptosis in Multiple Myeloma CellsSemantic proximity Read ↗

The pan-Bcl-2 inhibitor obatoclax promotes differentiation and apoptosis of acute myeloid leukemia cellsSemantic proximity Read ↗

Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cellsSemantic proximity Read ↗

Preclinical studies of the pan-Bcl inhibitor obatoclax (GX015-070) in multiple myelomaSemantic proximity Read ↗

Flavopiridol induces<i>BCL-2</i>expression and represses oncogenic transcription factors in leukemic blasts from adults with refractory acute myeloid leukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.